Element Pointe Advisors LLC Invests $836,000 in Thermo Fisher Scientific Inc. $TMO

Key Points

• Element Pointe Advisors initiated an approximately $836,000 position in Thermo Fisher Scientific during the second quarter, while institutional investors overall own 89.23% of the company.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 versus the $5.71 consensus estimate and revenue of $11.99 billion, up 10.5% year over year.
• The stock opened at $614.32, up 4.3%, and analysts maintain a “Moderate Buy” consensus with an average price target of $619.41; the company also declared a quarterly dividend of $0.47 per share.

Element Pointe Advisors LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,668 shares of the medical research company's stock, valued at approximately $836,000.

Other large investors have also recently bought and sold shares of the company. North Dakota State Investment Board bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $7,505,000. BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at $15,501,867,000. Hudson Value Partners LLC increased its holdings in Thermo Fisher Scientific by 24.9% during the second quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock worth $8,349,000 after buying an additional 3,317 shares during the last quarter. Boston Trust Walden Corp raised its position in Thermo Fisher Scientific by 9.7% during the fourth quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company's stock worth $25,480,000 after acquiring an additional 3,873 shares in the last quarter. Finally, Xponance LLC lifted its stake in Thermo Fisher Scientific by 8.1% in the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock valued at $34,358,000 after acquiring an additional 4,436 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 4.3%

Shares of TMO opened at $614.32 on Thursday. The firm has a market cap of $227.14 billion, a P/E ratio of 33.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The firm's 50-day simple moving average is $536.26 and its 200 day simple moving average is $508.51.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the business posted $4.28 earnings per share. The business's revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. This trade represents a 1.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares of the company's stock, valued at $1,734,546.46. This represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent analyst reports. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. KeyCorp reiterated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research note on Monday, July 6th. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective for the company. Finally, Wolfe Research started coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source